Depression

 
Nearly Half of Adults Diagnosed with MDD May Have Treatment Resistant Depression, Many Feel Hopeless
March 25, 2025

More than one-third of study participants with TRD had failed to get relief from 4 or more antidepressants, calling treatment experiences a "trial and error" process.

Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
February 27, 2025

Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.

Depression Increases Risk For and Accrual of Long-Term Health Disorders
February 21, 2025

Comorbid conditions accrued at a rate 30% faster among adults with depression than in those without the disorder over a 7-year follow-up period.

Vistagen Wins US Patent for Investigational NMDA Receptor Antagonist to Treat Neuropathic Pain
February 10, 2025

AV-101 is an orally bioavailable small molecule NMDA receptor antagonist with antinociceptive effects similar to gabapentin but with more a more favorable safety profile.

New Study Links Major Depressive Disorder to Specific Changes in Eating Preferences
February 06, 2025

People with MDD demonstrated a preference for carbohydrate-rich foods and reduced reward from fat- and protein-rich foods, according to new research.

Inhaled Psychedelic GH001 Significantly and Rapidly Reduces Symptoms in Treatment Resistant Depression in Phase 2b Clinical Trial
February 04, 2025

GH001, an inhalable 5-MeO-DMT therapy, led to a -15.5 MADRS score reduction by day 8 in patients with treatment-resistant depression.

FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
January 31, 2025

Your daily dose of the clinical news you may have missed.

Neurocrine Biosciences Launches Phase 3 Registration Program for Osavampator in Major Depressive Disorder
January 28, 2025

The investigational and potentially first-in-class therapy may enhance AMPA receptor sensitivity to glutamate, enhancing neuronal transmission.

3 Studies on Major Depressive Disorder: Physical, Pharmacologic, and Neuromodulatory Interventions Explored
January 24, 2025

Findings on the efficacy of treatments for MDD include the favorable effects of exercise, of CBT, and the robust outcomes of ECT among neuromodulatory modalities.

FDA Approves Esketamine as Monotherapy for Adults With Treatment-Resistant Depression
January 21, 2025

The approval of esketamine follows an FDA Priority Review and is based on data showing that esketamine alone demonstrated rapid and superior improvement in depressive symptoms compared with placebo.